Alzheimer’s disease CSF biomarkers correlate with early pathology and alterations in neuronal and glial gene expression

Competing Interest Statement

LSH reports grants from NIH, New York State Dept of Health, Lewy Body Disease Association, CurePSP, Abbvie, Acumen, Alector, Biogen, Bristol-Myer Squibb, Cognition, EIP, Eisai, Genentech/Roche, Janssen/Johnson and Johnson, Transposon Therapeutics, UCB, and Vaccinex, as well as consulting fees from Biogen, Corium, Eisai, Genentech/Roche, and New Amsterdam, Payment or honoraria from Eisai Pharmaceuticals, Medscape, and Biogen, Payment for expert testimony from Monsanto and legal firms, support for attending meetings and/or travel from Eisai Pharmaceuticals, participation on a data safety monitoring or advisory board from Prevail Therapeutics/Lilly, Cortexyme, and Eisai, and a leadership role in the Alzheimer's Association. GWM reports grant funding from NIH, CancerUK, Department of Defense (USAMRAA), Alley Corp, and SPARK-NS. AFT reports grant funding from NIH and Regeneron, stock ownership in Biogen and Ionis, paid committee work for DOD and NIH, and unpaid committee work for the Alzheimer's Association. RAM reports grants from NIH, Minnesota Partnership for Biotechnology and Genomics, Minnesota Robotics Institute, and MnDRIVE Data Science Initiative. GMM reports grants from NIH, consulting with Koh Young Inc and NeuroOne Technologies, participation on the Medronic SLATE trial Publication Committee, and leadership/committee roles in the Neurosurgical Society of America, AANS, and ASSFN. LMB reports support from NIH. The other authors have nothing to report.

Funding Statement

This study was supported by NIH grants K08-AG049938 (AFT), K76-AG054868 (AFT), R01-AG073360 (AFT/GMM), and P30-AG066462 (Small), and with support from the Thompson Family Foundation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Institutional Review Board of Columbia University gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes